GH Research clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
GH Research PLC
GHRS · Nasdaq · USD · Market cap $1.3B · 73 employees
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
Not enough data to screen yetPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price17.53 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.19x the price, above our 2.00x limit.
- Our regime readMarkdown, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 1.00)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.00, read 2026-11-20
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
GH Research PLC holds its Markdown at $17.53. Consolidating, no directional conviction, held for 93 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 93 days |
| Price at the screen | $17.53 |
| Valuation | N/A trailing · -10.41 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.32 |
Five Screens: GHRS's Results
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.03% | Below 33% | Pass |
| Interest-bearing cash | 18.71% | Below 33% | Pass |
| Receivables | 0.00% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadThe Read, in Plain English
GH Research clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
GH Research clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value under review. Our model's value is 2.19x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet. Average target +128%.
Inhalable Depression Drug Trading Below Fair Value
Depression still leaves too many patients with slow or incomplete relief from existing pills. GH Research is pushing an inhalable candidate through mid-stage trials that could reach the brain faster, and the shares sit 29 percent below the consensus fair value of 37 dollars with eight analysts calling the setup a strong buy.
The business remains early, burning cash with zero profit margin and a negative 20 percent return on equity, yet the ethical screen clears and the forward multiple reflects pre-revenue reality rather than distress. This leaves a margin of safety without the usual hype attached to clinical names.
Risk sits in the trial outcomes themselves. One failed Phase 2b read or any delay could wipe out the current discount quickly, and small biotechs in this field carry binary regulatory and funding exposure. Analysis, not advice.
| Forward P/E | -10.4x |
| EPS, trailing | -0.99 |
| EPS, forward | -1.85 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -18.8%not currently earning a positive return on equity |
| FCF yield | -2.76% |
| Debt to equity | 0.10minimal debt: a conservative balance sheet |
| Current ratio | 28.70comfortably covers its short-term bills |
| Beta | 1.32moves a little more than the market |
| Short interest, float | 0.07% |
| 52-week range | 12.04 - 31.44 |
| Market cap | $1.3B |
| Employees | 73 |
GHRS-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to Ireland and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Ethical screening: not fully scored yet (changed).
The framework has shifted from accumulation to markdown since the last review.
Ethical screening: PASS.
Written on its date, before the outcome; never pruned.
- GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update Yahoo Finance · 8d ago
- GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer Yahoo Finance · 8d ago
- GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger Yahoo Finance · 20d ago
- GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price Yahoo Finance · 18 Oct 2026
- GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update Yahoo Finance · 6 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $21.26 | -2.5% | · | $976 | -2.5% |
| 2 months | $15.72 | +31.9% | · | $1,319 | +31.9% |
| 3 months | $15.52 | +33.6% | · | $1,336 | +33.6% |
| 6 months | $13.80 | +50.3% | · | $1,503 | +50.3% |
| 1 year | $12.84 | +61.5% | · | $1,615 | +61.5% |
| 2 years | $12.01 | +72.7% | · | $1,727 | +72.7% |
| 3 years | $12.24 | +69.4% | · | $1,694 | +69.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GHRS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.